November 15, 2006
04:00 AM PST
PALO ALTO, Calif. - (BUSINESS WIRE) - Bayhill Therapeutics, Inc. a clinical stage biotechnology company developing innovative therapies for autoimmune diseases, has named Robert S. King, Ph.D. Vice President of Manufacturing. Dr. King will report to CEO Mark Schwartz and will be responsible for all manufacturing activities as the company moves its product candidates through clinical trials toward commercialization.
Dr. King brings more than 18 years of biotechnology industry experience to Bayhill. He most recently was the Vice President of Product Development and Manufacturing at Rinat Neuroscience Corp., a division of Pfizer Global Research and Development, where he was responsible for technical development of all product candidates. Previously, Dr. King was responsible for process development, formulations and manufacturing of all compounds in clinical development at Millennium Pharmaceuticals in South San Francisco and COR Therapeutics, where he oversaw product development of INTEGRILINTM injection from proof of concept to commercialization. He also served in various product development roles at Scios Inc., formerly California Biotechnology Inc., and Molecular Devices Corp.
Dr. King holds several patents related to manufacturing processes and his work has been published in numerous scientific journals. He holds a Ph.D. in Chemical Engineering from the University of California, Berkeley and a Bachelor of Science degree in Chemical Engineering from the University of Washington.
“We are extremely pleased to have Robert join Bayhill Therapeutics’ senior management team,” Dr. Schwartz said. “Robert’s breadth of manufacturing experience, including successfully moving product candidates through clinical trials to commercialization, will be invaluable to Bayhill as its antigen-specific DNA vaccines for multiple sclerosis and autoimmune diabetes progress through Phase II trials and potentially to market.”
“Bayhill has made significant progress in moving its technology through clinical development,” Dr. King commented. “I look forward to joining Bayhill’s excellent management team in order to support the late-stage development and commercialization efforts of the company’s exciting products.”
About Bayhill Therapeutics
Bayhill Therapeutics Inc. is a clinical-stage biotechnology company focused on developing and commercializing therapeutics that fundamentally alter the way autoimmune diseases are treated. The company has developed two therapeutic platforms with broad applicability to a range of autoimmune diseases. Bayhill’s BHT-DNA autoimmune vaccine is designed to eliminate disease-causing cells without affecting normal protective immune system cells. BHT-DNA is being studied in a recently completed Phase II trial for multiple sclerosis and a Phase I/II trial for autoimmune diabetes. Bayhill’s second therapeutic platform is an oligonucleotide; the first product candidate is in preclinical development for systemic lupus erythematosus.
More information about Bayhill Therapeutics is available at www.bayhilltx.com.
CONTACTS
Mark W. Schwartz, Ph.D.
President, CEO, Director
Bayhill Therapeutics Inc.
650-320-2800
mschwartz@bayhilltx.com
or
Fred Kurland
Chief Financial Officer
Bayhill Therapeutics Inc.
650-320-2800
fkurland@bayhilltx.com
or
Burns McClellan, on behalf of Bayhill Therapeutics, Inc.
Susan Thomas
415-352-6262 (Media)
sthomas@burnsmc.com
John Cummings
415-352-6262 (Investors)
jcummings@burnsmc.com
